InflaRx focuses on discovering and developing potent, specific inhibitors of the complement factor C5a. Its lead candidate IFX-1 is a first-in-class monoclonal anti-C5a antibody that blocks C5a while leaving the membrane attack complex intact. IFX-1 has been the first monoclonal anti-C5a advanced into clinical development and more than 150 people have been treated with the drug to date. The company completed a Phase IIa open-label trial in hidradenitis suppurativa that demonstrated disease‑modifying activity. Proceeds from the recent financing will be used to advance IFX-1 into a Phase IIb program for chronic inflammatory and autoimmune indications and to progress preclinical follow‑on molecules. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany, and its team includes experts in complement and clinical research. InflaRx focuses on developing breakthrough therapeutics that control inflammation resulting from terminal complement activation, with a lead asset IFX-1, a first-in-class anti-C5a monoclonal antibody. IFX-1 has completed a Phase IIa clinical trial in patients with early septic organ dysfunction in which all primary endpoints were met, and a second Phase II trial in complex cardiac surgery patients was initiated in June 2016. The company is also developing follow-up molecules IFX-2 and IFX-3 targeting chronic inflammation-related diseases. InflaRx plans to use proceeds from its financing to advance clinical Phase II development of IFX-1 across multiple acute and chronic inflammatory indications and to support preclinical development of its pipeline. The company highlights orphan drug potential for some indications and says IFX-1 selectively blocks C5a while leaving membrane attack complex formation intact. InflaRx was founded in 2007 and is headquartered in Jena, Germany, with a team of experts in complement and clinical research. InflaRx is a Jena-based biopharma developing first-in-class anti-complement monoclonal antibodies, including lead candidate IFX-1 and a follow-on antibody IFX-2. The company has initiated a phase IIa trial with IFX-1 (started in 2014) targeting infectious organ dysfunction in acutely site-specific septic patients and is setting up a second phase II trial to prevent systemic inflammation and organ dysfunction in large-scale surgery. Additional clinical programs are in the pipeline as InflaRx says it has enlarged its technology base to target both acute and chronic inflammatory diseases. The company also plans to develop a bedside complement activation test in collaboration with a diagnostic partner. InflaRx recently received the IQ Innovation Award in Germany. Management reports it has built a global network of private business investors and completed a round B financing to support its clinical and preclinical programs, with the round reaching an investment volume in the double-digit million euro range.

Total raised

$64M

Funding rounds

3

Latest round

Series D

Latest activity

Oct 2017